nodes	percent_of_prediction	percent_of_DWPC	metapath
Gefitinib—EGFR—cervical cancer	0.535	1	CbGaD
Gefitinib—ABCG2—Topotecan—cervical cancer	0.157	0.634	CbGbCtD
Gefitinib—ABCB1—Topotecan—cervical cancer	0.0565	0.229	CbGbCtD
Gefitinib—CYP3A4—Topotecan—cervical cancer	0.0339	0.137	CbGbCtD
Gefitinib—ERBB3—exocrine gland—cervical cancer	0.00325	0.0312	CbGeAlD
Gefitinib—SBK1—endometrium—cervical cancer	0.00238	0.0229	CbGeAlD
Gefitinib—Febrile neutropenia—Topotecan—cervical cancer	0.00219	0.0751	CcSEcCtD
Gefitinib—CHEK2—decidua—cervical cancer	0.00218	0.021	CbGeAlD
Gefitinib—Lapatinib—EGFR—cervical cancer	0.00216	0.351	CrCbGaD
Gefitinib—HIPK4—female reproductive system—cervical cancer	0.00195	0.0187	CbGeAlD
Gefitinib—Interstitial lung disease—Topotecan—cervical cancer	0.00186	0.0639	CcSEcCtD
Gefitinib—Pleural effusion—Topotecan—cervical cancer	0.00172	0.059	CcSEcCtD
Gefitinib—CHEK2—female gonad—cervical cancer	0.00156	0.015	CbGeAlD
Gefitinib—CHEK2—vagina—cervical cancer	0.00155	0.0149	CbGeAlD
Gefitinib—EPHA6—female reproductive system—cervical cancer	0.00154	0.0148	CbGeAlD
Gefitinib—Afatinib—EGFR—cervical cancer	0.00153	0.249	CrCbGaD
Gefitinib—EGFR—uterine cervix—cervical cancer	0.00151	0.0145	CbGeAlD
Gefitinib—CSNK1E—uterine cervix—cervical cancer	0.00145	0.014	CbGeAlD
Gefitinib—IRAK4—uterine cervix—cervical cancer	0.00143	0.0137	CbGeAlD
Gefitinib—ERBB3—epithelium—cervical cancer	0.00141	0.0136	CbGeAlD
Gefitinib—ERBB3—uterine cervix—cervical cancer	0.0014	0.0135	CbGeAlD
Gefitinib—MAP3K19—female reproductive system—cervical cancer	0.0014	0.0135	CbGeAlD
Gefitinib—CSNK1E—decidua—cervical cancer	0.00138	0.0133	CbGeAlD
Gefitinib—IRAK4—decidua—cervical cancer	0.00136	0.0131	CbGeAlD
Gefitinib—MKNK2—epithelium—cervical cancer	0.00134	0.0129	CbGeAlD
Gefitinib—Respiratory failure—Topotecan—cervical cancer	0.00134	0.046	CcSEcCtD
Gefitinib—MKNK2—uterine cervix—cervical cancer	0.00133	0.0128	CbGeAlD
Gefitinib—IRAK1—uterine cervix—cervical cancer	0.00133	0.0128	CbGeAlD
Gefitinib—EGFR—mammalian vulva—cervical cancer	0.00132	0.0127	CbGeAlD
Gefitinib—MKNK1—uterine cervix—cervical cancer	0.00132	0.0127	CbGeAlD
Gefitinib—CSNK1E—endometrium—cervical cancer	0.00131	0.0126	CbGeAlD
Gefitinib—ERBB3—renal system—cervical cancer	0.00131	0.0126	CbGeAlD
Gefitinib—IRAK4—endometrium—cervical cancer	0.00129	0.0124	CbGeAlD
Gefitinib—CSNK1E—mammalian vulva—cervical cancer	0.00127	0.0122	CbGeAlD
Gefitinib—MKNK2—decidua—cervical cancer	0.00127	0.0122	CbGeAlD
Gefitinib—IRAK1—decidua—cervical cancer	0.00127	0.0122	CbGeAlD
Gefitinib—EGFR—uterus—cervical cancer	0.00126	0.0121	CbGeAlD
Gefitinib—MKNK1—decidua—cervical cancer	0.00125	0.0121	CbGeAlD
Gefitinib—IRAK4—mammalian vulva—cervical cancer	0.00125	0.012	CbGeAlD
Gefitinib—MKNK2—renal system—cervical cancer	0.00125	0.012	CbGeAlD
Gefitinib—CSNK1E—uterus—cervical cancer	0.00121	0.0116	CbGeAlD
Gefitinib—MKNK2—endometrium—cervical cancer	0.00121	0.0116	CbGeAlD
Gefitinib—MKNK1—endometrium—cervical cancer	0.00119	0.0114	CbGeAlD
Gefitinib—ERBB3—uterus—cervical cancer	0.00117	0.0112	CbGeAlD
Gefitinib—MKNK2—mammalian vulva—cervical cancer	0.00117	0.0112	CbGeAlD
Gefitinib—IRAK1—mammalian vulva—cervical cancer	0.00117	0.0112	CbGeAlD
Gefitinib—SBK1—lymph node—cervical cancer	0.00115	0.0111	CbGeAlD
Gefitinib—MKNK1—mammalian vulva—cervical cancer	0.00115	0.0111	CbGeAlD
Gefitinib—MKNK2—uterus—cervical cancer	0.00111	0.0107	CbGeAlD
Gefitinib—CSNK1E—female reproductive system—cervical cancer	0.00109	0.0105	CbGeAlD
Gefitinib—STK10—uterine cervix—cervical cancer	0.00108	0.0104	CbGeAlD
Gefitinib—Erlotinib—EGFR—cervical cancer	0.00108	0.176	CrCbGaD
Gefitinib—ERBB3—female reproductive system—cervical cancer	0.00105	0.0101	CbGeAlD
Gefitinib—STK10—decidua—cervical cancer	0.00103	0.00993	CbGeAlD
Gefitinib—EGFR—female gonad—cervical cancer	0.00103	0.0099	CbGeAlD
Gefitinib—STK10—renal system—cervical cancer	0.00101	0.00975	CbGeAlD
Gefitinib—CHEK2—lymph node—cervical cancer	0.001	0.00965	CbGeAlD
Gefitinib—Dermatitis bullous—Topotecan—cervical cancer	0.001	0.0343	CcSEcCtD
Gefitinib—MKNK2—female reproductive system—cervical cancer	0.000999	0.0096	CbGeAlD
Gefitinib—IRAK1—female reproductive system—cervical cancer	0.000999	0.0096	CbGeAlD
Gefitinib—CSNK1E—female gonad—cervical cancer	0.00099	0.00952	CbGeAlD
Gefitinib—MKNK1—female reproductive system—cervical cancer	0.000986	0.00948	CbGeAlD
Gefitinib—CSNK1E—vagina—cervical cancer	0.000984	0.00946	CbGeAlD
Gefitinib—IRAK4—female gonad—cervical cancer	0.000975	0.00937	CbGeAlD
Gefitinib—IRAK4—vagina—cervical cancer	0.000969	0.00932	CbGeAlD
Gefitinib—MAP2K5—uterine cervix—cervical cancer	0.000968	0.0093	CbGeAlD
Gefitinib—ERBB3—female gonad—cervical cancer	0.000956	0.00919	CbGeAlD
Gefitinib—STK10—mammalian vulva—cervical cancer	0.000948	0.00912	CbGeAlD
Gefitinib—MAP2K5—decidua—cervical cancer	0.000922	0.00886	CbGeAlD
Gefitinib—MKNK2—female gonad—cervical cancer	0.000909	0.00874	CbGeAlD
Gefitinib—IRAK1—female gonad—cervical cancer	0.000909	0.00874	CbGeAlD
Gefitinib—STK10—uterus—cervical cancer	0.000903	0.00868	CbGeAlD
Gefitinib—MKNK2—vagina—cervical cancer	0.000903	0.00868	CbGeAlD
Gefitinib—MKNK1—female gonad—cervical cancer	0.000897	0.00863	CbGeAlD
Gefitinib—MKNK1—vagina—cervical cancer	0.000892	0.00857	CbGeAlD
Gefitinib—MAP2K5—endometrium—cervical cancer	0.000875	0.00841	CbGeAlD
Gefitinib—Aspartate aminotransferase increased—Topotecan—cervical cancer	0.000863	0.0296	CcSEcCtD
Gefitinib—MAP2K5—mammalian vulva—cervical cancer	0.000847	0.00814	CbGeAlD
Gefitinib—Alanine aminotransferase increased—Topotecan—cervical cancer	0.000845	0.0289	CcSEcCtD
Gefitinib—STK10—female reproductive system—cervical cancer	0.000812	0.00781	CbGeAlD
Gefitinib—Pneumonia—Topotecan—cervical cancer	0.000743	0.0254	CcSEcCtD
Gefitinib—STK10—female gonad—cervical cancer	0.000739	0.0071	CbGeAlD
Gefitinib—Infestation NOS—Topotecan—cervical cancer	0.000738	0.0253	CcSEcCtD
Gefitinib—Infestation—Topotecan—cervical cancer	0.000738	0.0253	CcSEcCtD
Gefitinib—STK10—vagina—cervical cancer	0.000734	0.00706	CbGeAlD
Gefitinib—MAP2K5—female reproductive system—cervical cancer	0.000725	0.00697	CbGeAlD
Gefitinib—Stomatitis—Topotecan—cervical cancer	0.00072	0.0247	CcSEcCtD
Gefitinib—Vandetanib—EGFR—cervical cancer	0.000711	0.116	CrCbGaD
Gefitinib—ORM1—endometrium—cervical cancer	0.000711	0.00683	CbGeAlD
Gefitinib—Hepatobiliary disease—Topotecan—cervical cancer	0.000698	0.0239	CcSEcCtD
Gefitinib—Epistaxis—Topotecan—cervical cancer	0.000696	0.0239	CcSEcCtD
Gefitinib—Haemoglobin—Topotecan—cervical cancer	0.000666	0.0228	CcSEcCtD
Gefitinib—Bosutinib—EGFR—cervical cancer	0.000665	0.108	CrCbGaD
Gefitinib—Haemorrhage—Topotecan—cervical cancer	0.000663	0.0227	CcSEcCtD
Gefitinib—EGFR—lymph node—cervical cancer	0.000662	0.00637	CbGeAlD
Gefitinib—MAP2K5—female gonad—cervical cancer	0.00066	0.00634	CbGeAlD
Gefitinib—MAP2K5—vagina—cervical cancer	0.000656	0.0063	CbGeAlD
Gefitinib—CSNK1E—lymph node—cervical cancer	0.000637	0.00612	CbGeAlD
Gefitinib—IRAK4—lymph node—cervical cancer	0.000627	0.00603	CbGeAlD
Gefitinib—ERBB3—lymph node—cervical cancer	0.000614	0.00591	CbGeAlD
Gefitinib—Angiopathy—Topotecan—cervical cancer	0.000601	0.0206	CcSEcCtD
Gefitinib—Mediastinal disorder—Topotecan—cervical cancer	0.000597	0.0205	CcSEcCtD
Gefitinib—ORM1—female reproductive system—cervical cancer	0.000589	0.00566	CbGeAlD
Gefitinib—Alopecia—Topotecan—cervical cancer	0.000586	0.0201	CcSEcCtD
Gefitinib—MKNK2—lymph node—cervical cancer	0.000584	0.00562	CbGeAlD
Gefitinib—IRAK1—lymph node—cervical cancer	0.000584	0.00562	CbGeAlD
Gefitinib—Malnutrition—Topotecan—cervical cancer	0.000577	0.0198	CcSEcCtD
Gefitinib—MKNK1—lymph node—cervical cancer	0.000577	0.00555	CbGeAlD
Gefitinib—Anaemia—Topotecan—cervical cancer	0.000533	0.0183	CcSEcCtD
Gefitinib—Angioedema—Topotecan—cervical cancer	0.000527	0.0181	CcSEcCtD
Gefitinib—Malaise—Topotecan—cervical cancer	0.00052	0.0178	CcSEcCtD
Gefitinib—Cough—Topotecan—cervical cancer	0.000504	0.0172	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Topotecan—cervical cancer	0.000488	0.0167	CcSEcCtD
Gefitinib—STK10—lymph node—cervical cancer	0.000475	0.00457	CbGeAlD
Gefitinib—ABCG2—uterine cervix—cervical cancer	0.000471	0.00453	CbGeAlD
Gefitinib—Infection—Topotecan—cervical cancer	0.000468	0.016	CcSEcCtD
Gefitinib—Nervous system disorder—Topotecan—cervical cancer	0.000462	0.0158	CcSEcCtD
Gefitinib—Thrombocytopenia—Topotecan—cervical cancer	0.000461	0.0158	CcSEcCtD
Gefitinib—Skin disorder—Topotecan—cervical cancer	0.000457	0.0157	CcSEcCtD
Gefitinib—CYP1A1—epithelium—cervical cancer	0.000451	0.00433	CbGeAlD
Gefitinib—Anorexia—Topotecan—cervical cancer	0.000449	0.0154	CcSEcCtD
Gefitinib—ABCG2—decidua—cervical cancer	0.000449	0.00431	CbGeAlD
Gefitinib—CYP1A1—uterine cervix—cervical cancer	0.000447	0.0043	CbGeAlD
Gefitinib—CYP3A5—uterine cervix—cervical cancer	0.000437	0.0042	CbGeAlD
Gefitinib—ABCG2—endometrium—cervical cancer	0.000426	0.00409	CbGeAlD
Gefitinib—MAP2K5—lymph node—cervical cancer	0.000424	0.00408	CbGeAlD
Gefitinib—Dyspnoea—Topotecan—cervical cancer	0.00042	0.0144	CcSEcCtD
Gefitinib—CYP1A1—renal system—cervical cancer	0.000418	0.00402	CbGeAlD
Gefitinib—ABCG2—mammalian vulva—cervical cancer	0.000412	0.00396	CbGeAlD
Gefitinib—Decreased appetite—Topotecan—cervical cancer	0.000409	0.014	CcSEcCtD
Gefitinib—CYP3A5—renal system—cervical cancer	0.000409	0.00393	CbGeAlD
Gefitinib—Gastrointestinal disorder—Topotecan—cervical cancer	0.000407	0.0139	CcSEcCtD
Gefitinib—Fatigue—Topotecan—cervical cancer	0.000406	0.0139	CcSEcCtD
Gefitinib—Constipation—Topotecan—cervical cancer	0.000403	0.0138	CcSEcCtD
Gefitinib—Pain—Topotecan—cervical cancer	0.000403	0.0138	CcSEcCtD
Gefitinib—ABCG2—uterus—cervical cancer	0.000392	0.00377	CbGeAlD
Gefitinib—CYP1A1—mammalian vulva—cervical cancer	0.000391	0.00376	CbGeAlD
Gefitinib—Gastrointestinal pain—Topotecan—cervical cancer	0.000385	0.0132	CcSEcCtD
Gefitinib—CYP2C19—vagina—cervical cancer	0.000376	0.00361	CbGeAlD
Gefitinib—Urticaria—Topotecan—cervical cancer	0.000374	0.0128	CcSEcCtD
Gefitinib—CYP1A1—uterus—cervical cancer	0.000373	0.00358	CbGeAlD
Gefitinib—Abdominal pain—Topotecan—cervical cancer	0.000372	0.0128	CcSEcCtD
Gefitinib—Body temperature increased—Topotecan—cervical cancer	0.000372	0.0128	CcSEcCtD
Gefitinib—Hypersensitivity—Topotecan—cervical cancer	0.000347	0.0119	CcSEcCtD
Gefitinib—ORM1—lymph node—cervical cancer	0.000344	0.00331	CbGeAlD
Gefitinib—Asthenia—Topotecan—cervical cancer	0.000338	0.0116	CcSEcCtD
Gefitinib—CYP1A1—female reproductive system—cervical cancer	0.000335	0.00322	CbGeAlD
Gefitinib—Pruritus—Topotecan—cervical cancer	0.000333	0.0114	CcSEcCtD
Gefitinib—CYP2C9—female reproductive system—cervical cancer	0.000322	0.0031	CbGeAlD
Gefitinib—Diarrhoea—Topotecan—cervical cancer	0.000322	0.011	CcSEcCtD
Gefitinib—ABCG2—female gonad—cervical cancer	0.000321	0.00309	CbGeAlD
Gefitinib—ABCG2—vagina—cervical cancer	0.000319	0.00307	CbGeAlD
Gefitinib—CYP3A4—renal system—cervical cancer	0.000307	0.00295	CbGeAlD
Gefitinib—CYP1A1—female gonad—cervical cancer	0.000305	0.00293	CbGeAlD
Gefitinib—CYP1A1—vagina—cervical cancer	0.000303	0.00291	CbGeAlD
Gefitinib—ALB—lymph node—cervical cancer	0.000302	0.0029	CbGeAlD
Gefitinib—CYP2D6—renal system—cervical cancer	0.000302	0.0029	CbGeAlD
Gefitinib—Vomiting—Topotecan—cervical cancer	0.000299	0.0103	CcSEcCtD
Gefitinib—CYP3A5—female gonad—cervical cancer	0.000298	0.00286	CbGeAlD
Gefitinib—Rash—Topotecan—cervical cancer	0.000297	0.0102	CcSEcCtD
Gefitinib—Dermatitis—Topotecan—cervical cancer	0.000297	0.0102	CcSEcCtD
Gefitinib—CYP3A5—vagina—cervical cancer	0.000296	0.00285	CbGeAlD
Gefitinib—Nausea—Topotecan—cervical cancer	0.00028	0.00958	CcSEcCtD
Gefitinib—CYP3A4—female reproductive system—cervical cancer	0.000246	0.00236	CbGeAlD
Gefitinib—CYP2D6—female reproductive system—cervical cancer	0.000242	0.00232	CbGeAlD
Gefitinib—ABCB1—epithelium—cervical cancer	0.000234	0.00225	CbGeAlD
Gefitinib—ABCB1—uterine cervix—cervical cancer	0.000232	0.00223	CbGeAlD
Gefitinib—ABCB1—decidua—cervical cancer	0.000221	0.00213	CbGeAlD
Gefitinib—CYP2D6—female gonad—cervical cancer	0.00022	0.00212	CbGeAlD
Gefitinib—ABCB1—renal system—cervical cancer	0.000217	0.00209	CbGeAlD
Gefitinib—ABCB1—endometrium—cervical cancer	0.00021	0.00202	CbGeAlD
Gefitinib—ABCG2—lymph node—cervical cancer	0.000206	0.00198	CbGeAlD
Gefitinib—ABCB1—mammalian vulva—cervical cancer	0.000203	0.00195	CbGeAlD
Gefitinib—CYP1A1—lymph node—cervical cancer	0.000196	0.00188	CbGeAlD
Gefitinib—ABCB1—uterus—cervical cancer	0.000193	0.00186	CbGeAlD
Gefitinib—ABCB1—female reproductive system—cervical cancer	0.000174	0.00167	CbGeAlD
Gefitinib—ABCB1—female gonad—cervical cancer	0.000158	0.00152	CbGeAlD
Gefitinib—ABCB1—vagina—cervical cancer	0.000157	0.00151	CbGeAlD
Gefitinib—ABCB1—lymph node—cervical cancer	0.000102	0.000978	CbGeAlD
Gefitinib—MKNK1—Disease—TERT—cervical cancer	5e-05	0.000636	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling by NGF—STAT3—cervical cancer	5e-05	0.000636	CbGpPWpGaD
Gefitinib—EGFR—Signaling by PDGF—MTOR—cervical cancer	4.98e-05	0.000634	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—AKAP13—cervical cancer	4.94e-05	0.000629	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—HLA-DPB1—cervical cancer	4.93e-05	0.000628	CbGpPWpGaD
Gefitinib—EGFR—Signaling by NGF—FGFR3—cervical cancer	4.93e-05	0.000627	CbGpPWpGaD
Gefitinib—EGFR—MAPK Signaling Pathway—CASP3—cervical cancer	4.88e-05	0.000621	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—NOTCH2—cervical cancer	4.87e-05	0.00062	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—FGFR3—cervical cancer	4.85e-05	0.000617	CbGpPWpGaD
Gefitinib—EPHA6—Developmental Biology—STAT3—cervical cancer	4.84e-05	0.000616	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—HLA-DQB1—cervical cancer	4.83e-05	0.000615	CbGpPWpGaD
Gefitinib—ERBB3—Signaling by NGF—STAT3—cervical cancer	4.82e-05	0.000613	CbGpPWpGaD
Gefitinib—IRAK1—Signaling by NGF—CASP3—cervical cancer	4.77e-05	0.000607	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—AKAP13—cervical cancer	4.76e-05	0.000606	CbGpPWpGaD
Gefitinib—EGFR—Signaling by SCF-KIT—STAT3—cervical cancer	4.72e-05	0.000601	CbGpPWpGaD
Gefitinib—EGFR—B Cell Activation—MTOR—cervical cancer	4.71e-05	0.0006	CbGpPWpGaD
Gefitinib—EGFR—Immune System—UBE3A—cervical cancer	4.6e-05	0.000585	CbGpPWpGaD
Gefitinib—MKNK1—Disease—FGFR3—cervical cancer	4.58e-05	0.000583	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling by NGF—EGFR—cervical cancer	4.54e-05	0.000578	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—HLA-DPB1—cervical cancer	4.53e-05	0.000576	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—WNT2—cervical cancer	4.52e-05	0.000575	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—CD8A—cervical cancer	4.51e-05	0.000574	CbGpPWpGaD
Gefitinib—EGFR—NGF signalling via TRKA from the plasma membrane—MTOR—cervical cancer	4.51e-05	0.000574	CbGpPWpGaD
Gefitinib—ABCB1—Allograft Rejection—CASP3—cervical cancer	4.51e-05	0.000574	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—AKAP13—cervical cancer	4.49e-05	0.000571	CbGpPWpGaD
Gefitinib—IRAK4—Innate Immune System—MTOR—cervical cancer	4.46e-05	0.000567	CbGpPWpGaD
Gefitinib—IRAK4—Innate Immune System—CD4—cervical cancer	4.45e-05	0.000566	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—HES1—cervical cancer	4.43e-05	0.000564	CbGpPWpGaD
Gefitinib—EGFR—Integrated Pancreatic Cancer Pathway—CASP3—cervical cancer	4.41e-05	0.000561	CbGpPWpGaD
Gefitinib—EPHA6—Developmental Biology—EGFR—cervical cancer	4.4e-05	0.00056	CbGpPWpGaD
Gefitinib—ERBB3—Signaling by NGF—EGFR—cervical cancer	4.38e-05	0.000557	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—CASP8—cervical cancer	4.32e-05	0.00055	CbGpPWpGaD
Gefitinib—EGFR—Disease—WNT2—cervical cancer	4.31e-05	0.000549	CbGpPWpGaD
Gefitinib—MKNK1—Disease—NOTCH1—cervical cancer	4.3e-05	0.000548	CbGpPWpGaD
Gefitinib—EGFR—Focal Adhesion—CTNNB1—cervical cancer	4.27e-05	0.000543	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—WNT5A—cervical cancer	4.27e-05	0.000543	CbGpPWpGaD
Gefitinib—EGFR—Integrated Pancreatic Cancer Pathway—CTNNB1—cervical cancer	4.25e-05	0.000541	CbGpPWpGaD
Gefitinib—EGFR—Downstream signal transduction—STAT3—cervical cancer	4.25e-05	0.00054	CbGpPWpGaD
Gefitinib—EGFR—EGF/EGFR Signaling Pathway—STAT3—cervical cancer	4.22e-05	0.000538	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—FGFR3—cervical cancer	4.21e-05	0.000535	CbGpPWpGaD
Gefitinib—EGFR—Spinal Cord Injury—TP53—cervical cancer	4.15e-05	0.000529	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—WNT5A—cervical cancer	4.11e-05	0.000523	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—HLA-DPB1—cervical cancer	4.11e-05	0.000523	CbGpPWpGaD
Gefitinib—IRAK1—Cytokine Signaling in Immune system—STAT3—cervical cancer	4.08e-05	0.000519	CbGpPWpGaD
Gefitinib—IRAK1—Signaling by NGF—STAT3—cervical cancer	4.01e-05	0.00051	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—HES1—cervical cancer	3.99e-05	0.000508	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—AKAP13—cervical cancer	3.97e-05	0.000505	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—HES1—cervical cancer	3.96e-05	0.000504	CbGpPWpGaD
Gefitinib—IRAK4—Innate Immune System—CTNNB1—cervical cancer	3.95e-05	0.000503	CbGpPWpGaD
Gefitinib—EGFR—Signaling by FGFR in disease—STAT3—cervical cancer	3.94e-05	0.000501	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—MTHFR—cervical cancer	3.9e-05	0.000496	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—TERT—cervical cancer	3.89e-05	0.000494	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—WNT5A—cervical cancer	3.87e-05	0.000493	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—TAAR6—cervical cancer	3.87e-05	0.000492	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—HLA-DQB1—cervical cancer	3.85e-05	0.00049	CbGpPWpGaD
Gefitinib—EGFR—Signaling by PDGF—STAT3—cervical cancer	3.85e-05	0.00049	CbGpPWpGaD
Gefitinib—ALB—Folate Metabolism—TP53—cervical cancer	3.81e-05	0.000485	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—NOTCH2—cervical cancer	3.79e-05	0.000482	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—FGFR3—cervical cancer	3.69e-05	0.00047	CbGpPWpGaD
Gefitinib—IRAK1—Signaling by NGF—EGFR—cervical cancer	3.64e-05	0.000464	CbGpPWpGaD
Gefitinib—EGFR—Direct p53 effectors—TP53—cervical cancer	3.62e-05	0.000461	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—CD8A—cervical cancer	3.6e-05	0.000458	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—CASP8—cervical cancer	3.6e-05	0.000458	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—FGFR3—cervical cancer	3.57e-05	0.000454	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—MTOR—cervical cancer	3.55e-05	0.000452	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—CD4—cervical cancer	3.55e-05	0.000451	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—HLA-DQB1—cervical cancer	3.54e-05	0.00045	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—TERT—cervical cancer	3.5e-05	0.000445	CbGpPWpGaD
Gefitinib—EGFR—NGF signalling via TRKA from the plasma membrane—STAT3—cervical cancer	3.49e-05	0.000444	CbGpPWpGaD
Gefitinib—EGFR—Signaling by NGF—MTOR—cervical cancer	3.47e-05	0.000441	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—WNT5A—cervical cancer	3.42e-05	0.000436	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—MTOR—cervical cancer	3.41e-05	0.000434	CbGpPWpGaD
Gefitinib—EGFR—Integrated Breast Cancer Pathway—TP53—cervical cancer	3.41e-05	0.000434	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—CD4—cervical cancer	3.41e-05	0.000433	CbGpPWpGaD
Gefitinib—ERBB3—Disease—HES1—cervical cancer	3.38e-05	0.00043	CbGpPWpGaD
Gefitinib—CHEK2—Cell Cycle—TP53—cervical cancer	3.36e-05	0.000428	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—NOTCH1—cervical cancer	3.35e-05	0.000426	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—CD8A—cervical cancer	3.3e-05	0.00042	CbGpPWpGaD
Gefitinib—EGFR—Disease—WNT5A—cervical cancer	3.27e-05	0.000416	CbGpPWpGaD
Gefitinib—MKNK1—Disease—MTOR—cervical cancer	3.23e-05	0.00041	CbGpPWpGaD
Gefitinib—MKNK1—Disease—CD4—cervical cancer	3.22e-05	0.00041	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—FGFR3—cervical cancer	3.21e-05	0.000409	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—HLA-DQB1—cervical cancer	3.21e-05	0.000408	CbGpPWpGaD
Gefitinib—EGFR—Signaling by NGF—CASP3—cervical cancer	3.19e-05	0.000406	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—CA9—cervical cancer	3.18e-05	0.000405	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—CASP8—cervical cancer	3.16e-05	0.000402	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—CTNNB1—cervical cancer	3.15e-05	0.000401	CbGpPWpGaD
Gefitinib—EGFR—MAPK Signaling Pathway—TP53—cervical cancer	3.13e-05	0.000398	CbGpPWpGaD
Gefitinib—IRAK4—Innate Immune System—EGFR—cervical cancer	3.13e-05	0.000398	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—HES1—cervical cancer	3.1e-05	0.000395	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—WNT2—cervical cancer	3.02e-05	0.000384	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—NOTCH1—cervical cancer	3.01e-05	0.000384	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—CD8A—cervical cancer	3e-05	0.000381	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—NOTCH2—cervical cancer	2.99e-05	0.000381	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—NOTCH1—cervical cancer	2.99e-05	0.00038	CbGpPWpGaD
Gefitinib—ERBB3—Disease—MTHFR—cervical cancer	2.97e-05	0.000378	CbGpPWpGaD
Gefitinib—ERBB3—Disease—TERT—cervical cancer	2.96e-05	0.000377	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—MTOR—cervical cancer	2.96e-05	0.000377	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—CD4—cervical cancer	2.95e-05	0.000376	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—FGFR3—cervical cancer	2.94e-05	0.000374	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—cervical cancer	2.94e-05	0.000374	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—NOTCH2—cervical cancer	2.89e-05	0.000367	CbGpPWpGaD
Gefitinib—CSNK1E—Cell Cycle—TP53—cervical cancer	2.88e-05	0.000367	CbGpPWpGaD
Gefitinib—MKNK1—Disease—CTNNB1—cervical cancer	2.86e-05	0.000364	CbGpPWpGaD
Gefitinib—EGFR—Integrated Pancreatic Cancer Pathway—TP53—cervical cancer	2.83e-05	0.00036	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—FGFR3—cervical cancer	2.81e-05	0.000358	CbGpPWpGaD
Gefitinib—EGFR—Immune System—HLA-DPB1—cervical cancer	2.75e-05	0.00035	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—TERT—cervical cancer	2.72e-05	0.000346	CbGpPWpGaD
Gefitinib—ERBB3—Disease—FGFR3—cervical cancer	2.72e-05	0.000346	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—FGFR3—cervical cancer	2.7e-05	0.000344	CbGpPWpGaD
Gefitinib—EGFR—Signaling by NGF—STAT3—cervical cancer	2.68e-05	0.000341	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—AKAP13—cervical cancer	2.65e-05	0.000337	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—CTNNB1—cervical cancer	2.62e-05	0.000334	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—MTOR—cervical cancer	2.6e-05	0.00033	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—CD4—cervical cancer	2.59e-05	0.00033	CbGpPWpGaD
Gefitinib—ERBB3—Disease—NOTCH1—cervical cancer	2.55e-05	0.000325	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—CASP8—cervical cancer	2.52e-05	0.00032	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—MTOR—cervical cancer	2.51e-05	0.000319	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—CD4—cervical cancer	2.5e-05	0.000319	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—FGFR3—cervical cancer	2.5e-05	0.000318	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—EGFR—cervical cancer	2.5e-05	0.000318	CbGpPWpGaD
Gefitinib—MKNK1—Disease—STAT3—cervical cancer	2.49e-05	0.000317	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—HES1—cervical cancer	2.45e-05	0.000312	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—FGFR3—cervical cancer	2.45e-05	0.000312	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—CASP8—cervical cancer	2.4e-05	0.000306	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—NOTCH2—cervical cancer	2.4e-05	0.000306	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—EGFR—cervical cancer	2.4e-05	0.000305	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—HES1—cervical cancer	2.37e-05	0.000301	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—NOTCH1—cervical cancer	2.34e-05	0.000298	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—CTNNB1—cervical cancer	2.3e-05	0.000293	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—WNT5A—cervical cancer	2.29e-05	0.000291	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—CA9—cervical cancer	2.28e-05	0.00029	CbGpPWpGaD
Gefitinib—MKNK1—Disease—EGFR—cervical cancer	2.27e-05	0.000288	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—MTOR—cervical cancer	2.26e-05	0.000287	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—cervical cancer	2.22e-05	0.000283	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—CTNNB1—cervical cancer	2.22e-05	0.000283	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—CA9—cervical cancer	2.16e-05	0.000274	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—TERT—cervical cancer	2.15e-05	0.000274	CbGpPWpGaD
Gefitinib—EGFR—Immune System—HLA-DQB1—cervical cancer	2.14e-05	0.000273	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—cervical cancer	2.14e-05	0.000273	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—CASP8—cervical cancer	2.09e-05	0.000267	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—EGFR—cervical cancer	2.08e-05	0.000264	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—CASP3—cervical cancer	2.08e-05	0.000264	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—TERT—cervical cancer	2.07e-05	0.000264	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—MTOR—cervical cancer	2.07e-05	0.000263	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—CD4—cervical cancer	2.07e-05	0.000263	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—STAT3—cervical cancer	2.01e-05	0.000255	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CD8A—cervical cancer	2e-05	0.000255	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—CTNNB1—cervical cancer	2e-05	0.000255	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—CTNNB1—cervical cancer	1.99e-05	0.000253	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—MTOR—cervical cancer	1.98e-05	0.000252	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—CD4—cervical cancer	1.97e-05	0.000251	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—FGFR3—cervical cancer	1.97e-05	0.000251	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—HES1—cervical cancer	1.97e-05	0.000251	CbGpPWpGaD
Gefitinib—ALB—Metabolism—CA9—cervical cancer	1.96e-05	0.00025	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—STAT3—cervical cancer	1.94e-05	0.000247	CbGpPWpGaD
Gefitinib—ERBB3—Disease—MTOR—cervical cancer	1.91e-05	0.000243	CbGpPWpGaD
Gefitinib—ERBB3—Disease—CD4—cervical cancer	1.91e-05	0.000243	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—FGFR3—cervical cancer	1.9e-05	0.000242	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—MTOR—cervical cancer	1.9e-05	0.000242	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—CD4—cervical cancer	1.9e-05	0.000241	CbGpPWpGaD
Gefitinib—EGFR—Disease—HES1—cervical cancer	1.88e-05	0.000239	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—NOTCH1—cervical cancer	1.85e-05	0.000236	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—CTNNB1—cervical cancer	1.84e-05	0.000234	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—EGFR—cervical cancer	1.82e-05	0.000232	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—NOTCH1—cervical cancer	1.79e-05	0.000227	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—CA9—cervical cancer	1.76e-05	0.000224	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—EGFR—cervical cancer	1.76e-05	0.000224	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—MTOR—cervical cancer	1.76e-05	0.000224	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—CTNNB1—cervical cancer	1.75e-05	0.000223	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—STAT3—cervical cancer	1.75e-05	0.000222	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—STAT3—cervical cancer	1.73e-05	0.00022	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—TERT—cervical cancer	1.73e-05	0.00022	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—MTOR—cervical cancer	1.72e-05	0.000219	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—CA9—cervical cancer	1.72e-05	0.000219	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—CD4—cervical cancer	1.72e-05	0.000219	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—cervical cancer	1.7e-05	0.000216	CbGpPWpGaD
Gefitinib—ERBB3—Disease—CTNNB1—cervical cancer	1.69e-05	0.000216	CbGpPWpGaD
Gefitinib—EGFR—Disease—MTHFR—cervical cancer	1.65e-05	0.00021	CbGpPWpGaD
Gefitinib—EGFR—Disease—TERT—cervical cancer	1.65e-05	0.00021	CbGpPWpGaD
Gefitinib—EGFR—Immune System—FGFR3—cervical cancer	1.64e-05	0.000208	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CA9—cervical cancer	1.62e-05	0.000206	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—CASP3—cervical cancer	1.62e-05	0.000206	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CA9—cervical cancer	1.61e-05	0.000205	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—NOTCH2—cervical cancer	1.61e-05	0.000204	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—STAT3—cervical cancer	1.6e-05	0.000204	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—EGFR—cervical cancer	1.59e-05	0.000202	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—FGFR3—cervical cancer	1.58e-05	0.000202	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—CTNNB1—cervical cancer	1.56e-05	0.000198	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—CTNNB1—cervical cancer	1.53e-05	0.000194	CbGpPWpGaD
Gefitinib—EGFR—Disease—FGFR3—cervical cancer	1.51e-05	0.000192	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—NOTCH1—cervical cancer	1.49e-05	0.000189	CbGpPWpGaD
Gefitinib—ERBB3—Disease—STAT3—cervical cancer	1.48e-05	0.000188	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—EGFR—cervical cancer	1.45e-05	0.000185	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—cervical cancer	1.43e-05	0.000181	CbGpPWpGaD
Gefitinib—EGFR—Disease—NOTCH1—cervical cancer	1.42e-05	0.000181	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CASP8—cervical cancer	1.4e-05	0.000178	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—MTOR—cervical cancer	1.39e-05	0.000177	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—STAT3—cervical cancer	1.36e-05	0.000173	CbGpPWpGaD
Gefitinib—ERBB3—Disease—EGFR—cervical cancer	1.34e-05	0.000171	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—MTOR—cervical cancer	1.34e-05	0.00017	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—TP53—cervical cancer	1.33e-05	0.000169	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—STAT3—cervical cancer	1.33e-05	0.000169	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—HES1—cervical cancer	1.32e-05	0.000168	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—MTHFR—cervical cancer	1.29e-05	0.000164	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—CASP3—cervical cancer	1.28e-05	0.000163	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—EGFR—cervical cancer	1.23e-05	0.000157	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—CTNNB1—cervical cancer	1.23e-05	0.000157	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—CASP3—cervical cancer	1.23e-05	0.000157	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—EGFR—cervical cancer	1.21e-05	0.000154	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—CTNNB1—cervical cancer	1.19e-05	0.000151	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—TERT—cervical cancer	1.15e-05	0.000147	CbGpPWpGaD
Gefitinib—EGFR—Immune System—MTOR—cervical cancer	1.15e-05	0.000147	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CD4—cervical cancer	1.15e-05	0.000146	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—MTOR—cervical cancer	1.11e-05	0.000142	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—STAT3—cervical cancer	1.07e-05	0.000137	CbGpPWpGaD
Gefitinib—EGFR—Disease—MTOR—cervical cancer	1.06e-05	0.000135	CbGpPWpGaD
Gefitinib—EGFR—Disease—CD4—cervical cancer	1.06e-05	0.000135	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CA9—cervical cancer	1.06e-05	0.000135	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—FGFR3—cervical cancer	1.06e-05	0.000135	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—TP53—cervical cancer	1.04e-05	0.000132	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—STAT3—cervical cancer	1.03e-05	0.000132	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CASP3—cervical cancer	1.02e-05	0.00013	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CTNNB1—cervical cancer	1.02e-05	0.00013	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—NOTCH1—cervical cancer	9.94e-06	0.000127	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CTNNB1—cervical cancer	9.88e-06	0.000126	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—EGFR—cervical cancer	9.75e-06	0.000124	CbGpPWpGaD
Gefitinib—EGFR—Disease—CTNNB1—cervical cancer	9.43e-06	0.00012	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—EGFR—cervical cancer	9.4e-06	0.00012	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—MTHFR—cervical cancer	9.26e-06	0.000118	CbGpPWpGaD
Gefitinib—EGFR—Immune System—STAT3—cervical cancer	8.91e-06	0.000113	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—MTHFR—cervical cancer	8.75e-06	0.000111	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—STAT3—cervical cancer	8.61e-06	0.00011	CbGpPWpGaD
Gefitinib—EGFR—Disease—STAT3—cervical cancer	8.22e-06	0.000105	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—TP53—cervical cancer	8.19e-06	0.000104	CbGpPWpGaD
Gefitinib—ALB—Metabolism—MTHFR—cervical cancer	7.97e-06	0.000101	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—TP53—cervical cancer	7.89e-06	0.0001	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—EGFR—cervical cancer	7.83e-06	9.96e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—TP53—cervical cancer	7.47e-06	9.5e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MTOR—cervical cancer	7.45e-06	9.48e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—MTHFR—cervical cancer	7.16e-06	9.11e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—MTHFR—cervical cancer	6.99e-06	8.89e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CASP3—cervical cancer	6.85e-06	8.72e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CTNNB1—cervical cancer	6.61e-06	8.41e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—MTHFR—cervical cancer	6.58e-06	8.38e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—TP53—cervical cancer	6.57e-06	8.36e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—MTHFR—cervical cancer	6.53e-06	8.3e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—STAT3—cervical cancer	5.76e-06	7.33e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—TP53—cervical cancer	4.39e-06	5.59e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—MTHFR—cervical cancer	4.3e-06	5.48e-05	CbGpPWpGaD
